181 related articles for article (PubMed ID: 33845814)
1. Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma.
Aicher WK; Korn M; Reitnauer L; Maurer FB; Hennenlotter J; Black PC; Todenhofer T; Bedke J; Stenzl A
BMC Urol; 2021 Apr; 21(1):60. PubMed ID: 33845814
[TBL] [Abstract][Full Text] [Related]
2. Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation.
Harland N; Maurer FB; Abruzzese T; Bock C; Montes-Mojarro IA; Fend F; Aicher WK; Stenzl A; Amend B
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563359
[TBL] [Abstract][Full Text] [Related]
3. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
5. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
8. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
9. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.
Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D
Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773
[TBL] [Abstract][Full Text] [Related]
10. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.
Fauconnet S; Bernardini S; Lascombe I; Boiteux G; Clairotte A; Monnien F; Chabannes E; Bittard H
Oncol Rep; 2009 Jun; 21(6):1495-504. PubMed ID: 19424629
[TBL] [Abstract][Full Text] [Related]
11. CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.
Choi JW; Kim Y; Lee JH; Kim YS
Int J Urol; 2013 Feb; 20(2):251-5. PubMed ID: 22905972
[TBL] [Abstract][Full Text] [Related]
12. The relation between Ring Box-1 protein overexpression and tumor grade and stage in bladder urothelial cell carcinoma.
Celik ZE; Kaynar M; Karabagli P; Gergerlioglu N; Goktas S
Cancer Biomark; 2017 Dec; 20(4):389-394. PubMed ID: 28946546
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma.
Croft PR; Lathrop SL; Feddersen RM; Joste NE
Arch Pathol Lab Med; 2005 Feb; 129(2):194-9. PubMed ID: 15679420
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
15. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
16. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
[TBL] [Abstract][Full Text] [Related]
17. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
18. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
[TBL] [Abstract][Full Text] [Related]
19. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
20. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
Zhu L; Liu X; Zhang W; Hu H; Wang Q; Xu K
BMC Cancer; 2022 May; 22(1):556. PubMed ID: 35581573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
